Abatacept

PBAC's latest decision on Abatacept: Recommended with restriction (2018). Considered for Treatment of severe active psoriatic arthritis (PsA) in adults who have failed to achieve an adequate response to conventional non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

Eligible population

Adults with severe active psoriatic arthritis who have failed to achieve an adequate response to methotrexate (at least 20 mg weekly for minimum 3 months) and sulfasalazine (at least 2 g daily for minimum 3 months) or leflunomide (up to 20 mg daily for minimum 3 months), and who have received no prior PBS-subsidised biologic agent or none for at least 5 years.

Therapy area

Rheumatology

Line of therapy

Later-line

Evidence base

RCT

Primary endpoint

ACR20

Pivotal trial size

424 patients

Key trials

Mease 2011, Mease 2017 (ASTRAEA), RAPID-PsA, PSUMMIT 1, PSUMMIT 2, FUTURE 2

Comparator

certolizumab pegol, ustekinumab, secukinumab

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis conducted; no numeric ICER calculated or stated.

Submission history

• Nov 2007: Recommended · Restricted
• Jul 2011: Not recommended
• Nov 2015: Recommended · Authority Required
• Mar 2018: Recommended with restriction · Authority Required

Similar precedents

• Etanercept
  similarity 0.72
• Methotrexate
  similarity 0.71
• Apremilast
  similarity 0.69
• Bimekizumab
  similarity 0.69
• Adalimumab
  similarity 0.69
• Secukinumab
  similarity 0.69